PDF(Sci-hub)
Abstract：
Vaccination is an effective strategy to combat invasive meningococcal disease (IMD). Vaccines against the major disease-causing meningococcal serogroups are available; however, development of vaccines against serogroup B faced particular challenges, including the inability to target traditional meningococcal antigens (i.e. polysaccharide capsule) and limited alternative antigens due to serogroup B strain diversity. Two different recombinant, protein-based, serogroup B (MenB) vaccines that may address these challenges are currently available. These vaccines have been extensively evaluated in pre-licensure safety and immunogenicity trials, and recently in real-world studies on effectiveness, safety, and impact on disease burden.
This review provides healthcare professionals, particularly pediatricians, an overview of currently available MenB vaccines, including development strategies and evaluation of coverage.
Overall, recombinant MenB vaccines are valuable tools for healthcare professionals to protect patients against IMD. Their development required innovative design approaches that overcame challenging hurdles and identified novel protein antigen targets; however, important distinctions in the approaches used in their development, evaluation, and administration exist and many unanswered questions remain. Healthcare providers frequently prescribing MenB vaccines are challenged to keep abreast of these differences to ensure patient protection against this serious disease.
This review provides healthcare professionals, particularly pediatricians, an overview of currently available MenB vaccines, including development strategies and evaluation of coverage.
Overall, recombinant MenB vaccines are valuable tools for healthcare professionals to protect patients against IMD. Their development required innovative design approaches that overcame challenging hurdles and identified novel protein antigen targets; however, important distinctions in the approaches used in their development, evaluation, and administration exist and many unanswered questions remain. Healthcare providers frequently prescribing MenB vaccines are challenged to keep abreast of these differences to ensure patient protection against this serious disease.
摘要：
疫苗接种是对抗侵袭性脑膜炎球菌病(IMD)的有效策略。有针对主要致病脑膜炎球菌血清群的疫苗；然而，针对血清群B的疫苗开发面临特殊挑战，包括无法靶向传统的脑膜炎球菌抗原（即多糖胶囊）和由于血清群B菌株多样性而导致的有限的替代抗原。两种不同的重组，基于蛋白质，目前可获得可以应对这些挑战的血清群B(MenB)疫苗。这些疫苗已在许可前安全性和免疫原性试验中进行了广泛评估，最近在现实世界的有效性研究中，安全,以及对疾病负担的影响。
这篇评论为医疗保健专业人员提供了，尤其是儿科医生，目前可用的MenB疫苗的概述，包括发展战略和覆盖面评估。
总的来说，重组MenB疫苗是医疗保健专业人员保护患者免受IMD侵害的宝贵工具。他们的发展需要创新的设计方法，克服具有挑战性的障碍，并确定新的蛋白质抗原靶标;然而，在他们的发展中使用的方法的重要区别，评估，和管理存在，许多悬而未决的问题仍然存在。经常处方MenB疫苗的医疗保健提供者面临挑战，要跟上这些差异，以确保患者免受这种严重疾病的侵害。
这篇评论为医疗保健专业人员提供了，尤其是儿科医生，目前可用的MenB疫苗的概述，包括发展战略和覆盖面评估。
总的来说，重组MenB疫苗是医疗保健专业人员保护患者免受IMD侵害的宝贵工具。他们的发展需要创新的设计方法，克服具有挑战性的障碍，并确定新的蛋白质抗原靶标;然而，在他们的发展中使用的方法的重要区别，评估，和管理存在，许多悬而未决的问题仍然存在。经常处方MenB疫苗的医疗保健提供者面临挑战，要跟上这些差异，以确保患者免受这种严重疾病的侵害。
